Cecilia Nisticò
Yahoo!
79 Papers
572 Citations
Cecilia Nisticò is an academic researcher from Yahoo!. The author has contributed to research in topics: Breast cancer & Metastatic breast cancer. The author has an hindex of 25, co-authored 77 publications.
Chat about Author
Papers
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
Federica Cuppone,Emilio Bria,Sunil Verma,Kathleen I. Pritchard,Sonal Gandhi,Paolo Carlini,Michelle Milella,Cecilia Nisticò,Edmondo Terzoli,Francesco Cognetti,Diana Giannarelli +10 more
TL;DR: Despite the advantages from using aromatase inhibitors compared with tamoxifen for early breast cancer, an unexpectedly greater number of grade 3 and 4 cardiovascular events (CVAE) was demonstrated.
126
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: An observational prospective study
Flavia Novelli,Michele Milella,Elisa Melucci,Anna Di Benedetto,Isabella Sperduti,Raffaele Perrone-Donnorso,Letizia Perracchio,Irene Venturo,Cecilia Nisticò,Alessandra Fabi,Simonetta Buglioni,Pier Giorgio Natali,Marcella Mottolese +12 more
TL;DR: The data indicated that, in contrast to node-negative patients, in node-positive breast cancer patients, ER-β positivity appears to be a biomarker related to a more aggressive clinical course, and it is necessary to better assess the role of the different ER- β isophorms.
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.
Emilio Bria,Michele Milella,Alain Gelibter,Federica Cuppone,Maria Simona Pino,Enzo Maria Ruggeri,Paolo Carlini,Cecilia Nisticò,Edmondo Terzoli,Francesco Cognetti,Diana Giannarelli +10 more
TL;DR: Several attempts have been made at improving the efficacy of gemcitabine in advanced pancreatic cancer by combining it with other chemotherapeutic or molecularly targeted agents, but randomized trials have produced conflicting results.
88
Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide
Paola Papaldo,Massimo Lopez,Enrico Cortesi,Eugenio Cammilluzzi,Mauro Antimi,Edmondo Terzoli,Giuseppe Lepidini,Patrizia Vici,Carlo Barone,Gianluigi Ferretti,Serena Di Cosimo,Cecilia Nisticò,Paolo Carlini,Francesca Conti,Luigi Di Lauro,Claudio Botti,Carlo Vitucci,Alessandra Fabi,Diana Giannarelli,Paolo Marolla +19 more
TL;DR: EC is active and well tolerated in patients with early breast cancer, and G-CSF dramatically reduced hematologic toxicity without having a significant impact on dose-intensity.
83
Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials
Emilio Bria,Federica Cuppone,Mariangela Ciccarese,Cecilia Nisticò,Francesco Facciolo,Michele Milella,Fiorentino Izzo,Edmondo Terzoli,Francesco Cognetti,Diana Giannarelli +9 more
TL;DR: The significant benefit in grade 3-4 neutropenia seems to suggest this approach in patients with NSCLC pretreated for advanced disease, although considering all drawbacks related to literature-based meta-analyses, weekly docetaxel seems not to improve survival when compared to 3-weekly docetAXel.
66